Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Temporal Interference, Sham Temporal Interference Stimulation.
- Who it may be relevant to
- Registry conditions: Essential Hypertension. Basic parameters: 30 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension: A Prospective, Double-blind, Randomized Controlled Trial
Overview
The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for blood pressure modulation in patients with mild essential hypertension.
Detailed description
This project aims to include 60 participants, who are randomly assigned in a 1 ratio into two groups named TI group and sham TI group , and evaluate the effectiveness and safety of temporal interference stimulation in patients with mild essential hypertension and through A prospective, double-blind, randomized controlled clinical trial. It is expected to provide new therapeutic options for patients with mild essential hypertension with alternative treatment options.
Interventions
- Device Temporal Interference
The Non-invasive transcranial temporal interference stimulation will consist of 14 days of 20-min temporal interference stimulation. - Device Sham Temporal Interference Stimulation
The sham (inactive) temporal interference stimulation will consist of 5 days of 20-min temporal interference stimulation.
Primary outcome measures
- 24-hour average systolic blood pressure (24h SBP) [Time frame: Up to 12 weeks after temporal interference stimulation]
Eligibility criteria
Inclusion criteria
- Aged between 30 and 65 years old.
- Office blood pressure with systolic blood pressure (SBP) 140-159 mmHg and/or diastolic blood pressure (DBP) 90-99 mmHg.
- No intake of any antihypertensive drugs or have discontinued antihypertensive medication for at least 3 months prior to randomization; no intention to receive any other antihypertensive therapy within the 15-week study period.
- Written informed consent has been obtained from the subject or their legally authorized representative after being informed of the potential risks.
Exclusion criteria
- Known or suspected secondary hypertension.
- Contraindications to TI treatment or sham TI treatment, including intracranial metal implants (e.g., pacemaker, ventriculoperitoneal shunt, vascular clip), craniocerebral surgery within the last 6 months, history of intracranial tumor or hemorrhage; skin damage, infection, eczema or allergy at the stimulation site (frontal/temporal region); severe skin diseases (e.g., psoriasis).
- Subjects with high risk of cerebrovascular disease indicated by cranial magnetic resonance imaging.
- History of myocardial infarction or cerebral infarction.
- Atrial fibrillation or other severe arrhythmias, such as severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia.
- Severe or unstable medical conditions, including severe hepatic dysfunction (defined as alanine transaminase or aspartate transaminase level more than 2 times the upper limit of normal), severe renal dysfunction (defined as serum creatinine level more than 1.5 times the upper limit of normal), and severe heart failure (New York Heart Association Class III and IV).
- Females who are pregnant, breastfeeding, or planning to become pregnant within one year.
- Individuals unable to cooperate due to mental illness or other reasons.
- Participants enrolled in other clinical trials within 3 months prior to randomization.
- Participants deemed ineligible for this trial for other reasons determined by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Xuanwu Hospital,Capital Medical University — Beijing
Identifiers
NCT: NCT07577323 · 2026-128-001